Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy
Author(s): Martin David Harp Key Takeaways Vantage Biosciences has begun a phase 2 trial for VX-01, targeting moderate to severe NPDR without CI-DME. The study is double masked, randomized, placebo…